Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gossamer Bio (GOSS) Revenue (2022 - 2025)

Gossamer Bio's Revenue history spans 4 years, with the latest figure at $13.8 million for Q4 2025.

  • For Q4 2025, Revenue rose 47.13% year-over-year to $13.8 million; the TTM value through Dec 2025 reached $48.5 million, down 57.74%, while the annual FY2025 figure was $48.5 million, 57.74% down from the prior year.
  • Revenue reached $13.8 million in Q4 2025 per GOSS's latest filing, up from $13.3 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $95.8 million in Q2 2024 to a low of -$3.5 million in Q1 2023.
  • Average Revenue over 4 years is $12.1 million, with a median of $9.4 million recorded in 2024.
  • The largest YoY upside for Revenue was 47.13% in 2025 against a maximum downside of 88.01% in 2025.
  • A 4-year view of Revenue shows it stood at -$3.5 million in 2022, then decreased by 1.24% to -$3.5 million in 2023, then surged by 367.97% to $9.4 million in 2024, then soared by 47.13% to $13.8 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's Revenue are $13.8 million (Q4 2025), $13.3 million (Q3 2025), and $11.5 million (Q2 2025).